Literature DB >> 15885321

Spinal cord injury induces early and persistent lesional P2X4 receptor expression.

Jan M Schwab1, Lianghao Guo, Hermann J Schluesener.   

Abstract

Following spinal cord injury (SCI), neuropathic, chronic pain is a major cause of disability. Recently, glial P2X4 receptor (P2X4R) has been identified as a major contributor to the development of neuropathic pain after peripheral nerve injury. Here we report analysis of P2X4R expression following rat SCI. Significant lesional accumulation of P2X4R+ cells was detected as early as 24 h after SCI, reaching maximum cell numbers on Day 7. Thereafter cell numbers declined but persisted at significantly elevated, sub-maximal levels (>70%) until 1 month post injury. Double-immunolabeling identified the majority of lesional P2X4R+ cells as activated microglia/macrophages and surviving neurons/neurites. Increase of P2X4R+, beta-APP+ hypertrophic neurites correlated with proximity to the lesion. Further, P2X4R+ cells coexpressed the intracellular regulators of signalling cascades, COX-1 (>20%), COX-2 (>5%), RhoA (>60%) and RhoB (>10%).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15885321     DOI: 10.1016/j.jneuroim.2005.02.016

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  30 in total

1.  CCL2 promotes P2X4 receptor trafficking to the cell surface of microglia.

Authors:  Emika Toyomitsu; Makoto Tsuda; Tomohiro Yamashita; Hidetoshi Tozaki-Saitoh; Yoshitaka Tanaka; Kazuhide Inoue
Journal:  Purinergic Signal       Date:  2012-01-06       Impact factor: 3.765

Review 2.  Molecular and functional properties of P2X receptors--recent progress and persisting challenges.

Authors:  Karina Kaczmarek-Hájek; Eva Lörinczi; Ralf Hausmann; Annette Nicke
Journal:  Purinergic Signal       Date:  2012-05-01       Impact factor: 3.765

3.  P2X4 receptors influence inflammasome activation after spinal cord injury.

Authors:  Juan Pablo de Rivero Vaccari; Dominic Bastien; Geoffrey Yurcisin; Isabelle Pineau; W Dalton Dietrich; Yves De Koninck; Robert W Keane; Steve Lacroix
Journal:  J Neurosci       Date:  2012-02-29       Impact factor: 6.167

4.  Estrogen and P2 Purinergic Receptor Systems in Microglia: Therapeutic Targets for Neuroprotection.

Authors:  Jessica M Crain; Jyoti J Watters
Journal:  Open Drug Discov J       Date:  2010-01-01

Review 5.  Pharmacology of P2X channels.

Authors:  Joel R Gever; Debra A Cockayne; Michael P Dillon; Geoffrey Burnstock; Anthony P D W Ford
Journal:  Pflugers Arch       Date:  2006-04-29       Impact factor: 3.657

Review 6.  P2X3 receptor involvement in pain states.

Authors:  Kerstin Wirkner; Beata Sperlagh; Peter Illes
Journal:  Mol Neurobiol       Date:  2007-07-17       Impact factor: 5.590

Review 7.  Molecular dialogs between the ischemic brain and the peripheral immune system: dualistic roles in injury and repair.

Authors:  Chengrui An; Yejie Shi; Peiying Li; Xiaoming Hu; Yu Gan; Ruth A Stetler; Rehana K Leak; Yanqin Gao; Bao-Liang Sun; Ping Zheng; Jun Chen
Journal:  Prog Neurobiol       Date:  2013-12-26       Impact factor: 11.685

8.  Amyloid-beta induces a caspase-mediated cleavage of P2X4 to promote purinotoxicity.

Authors:  R Varma; Y Chai; J Troncoso; J Gu; H Xing; S S Stojilkovic; M P Mattson; N J Haughey
Journal:  Neuromolecular Med       Date:  2009-06-27       Impact factor: 3.843

Review 9.  Neurobiology of microglial action in CNS injuries: receptor-mediated signaling mechanisms and functional roles.

Authors:  Xiaoming Hu; Anthony K F Liou; Rehana K Leak; Mingyue Xu; Chengrui An; Jun Suenaga; Yejie Shi; Yanqin Gao; Ping Zheng; Jun Chen
Journal:  Prog Neurobiol       Date:  2014-06-09       Impact factor: 11.685

10.  P2X4-receptor-mediated synthesis and release of brain-derived neurotrophic factor in microglia is dependent on calcium and p38-mitogen-activated protein kinase activation.

Authors:  Tuan Trang; Simon Beggs; Xiang Wan; Michael W Salter
Journal:  J Neurosci       Date:  2009-03-18       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.